Trial Profile

A Phase I Study of FID-007 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Biliary cancer; Carcinoma; Head and neck cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man

Most Recent Events

04 Jun 2024 Patients (n=46) were enrolled, according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
04 Jun 2024 Results (n=9) assessing safety and efficacy data in HNSCC patients, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
09 Feb 2024 Planned End Date changed from 25 May 2025 to 25 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com